Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
帕利他米(Pasritamig)是一种首创的双特异性T细胞衔接剂,靶向人激肽释放酶2,用于治疗转移性去势抵抗性前列腺癌:一项I期研究
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-00678
Stein, Mark N; Vinceneux, Armelle; Robbrecht, Debbie; Doger, Bernard; Autio, Karen A; Schweizer, Michael T; Calvo, Emiliano; Medina, Laura; Van Dongen, Marloes; Deville, Jean-Laurent; Bernard-Tessier, Alice; Ghosh, Debopriya; Shotts, Kristin; Shen, Fei; Jaiprasart, Pharavee; Chaudhary, Ruchi; Wu, Shujian; Cartee, Leanne; Schnepp, Robert; Gaut, Daria; Lauring, Josh; Wang, Sherry C; Villalobos, Victor M; Baldini, Capucine
肿瘤
T细胞
肿瘤免疫
Human
T细胞
细胞生物学
前列腺癌
免疫/内分泌